Pre-Filled Syringes & Injectable Drug Devices Europe 2018

SMi Group16 - 17 January 2019, London, UK.
The conference will offer a deep insight into key areas within the field, such as: new technologies and overcoming their hurdles to implementation; connectivity for devices; updates on drug development and the impact on device developments and new regulatory guidelines. The line-up of expert speakers will enable delegates to learn from market leaders on best practices to overcome common industry hurdles.

Join Pre-Filled Syringes & Injectable Drug Devices Europe in January 2019 to network, benchmark and learn about developments at the forefront of the Pre-Filled Syringes and Injectable Drug Devices industry.

Chairs for 2019

  • James Mellman, Device Manager, Novartis
  • Anil Busimi, Strategy and Innovation Global Product Manager, SCHOTT

Featured Speakers

  • Anil Busimi, Strategy and Innovation Global Product Manager, SCHOTT
  • Cedric Gysel, Staff Device Engineer, Janssen
  • Davide Mercadante, Sr Associate Quality Drug Devices, Biogen
  • Elise Legendre, Head of Late stage PFS Development, Sanofi
  • James Mellman, Device Manager, Novartis
  • Joan Malmstrom, Principal Scientist, Novo Nordisk
  • Justin Wright, Global Head of Innovation, Novartis
  • Maggie Reiff, Associate Device Engineer, Pfizer
  • Mathieu Rigollet, Senior PFS Engineer, Roche
  • Michael Becker, Design Engineer, Boehringer Ingelheim
  • Reinhard Scheller, Commercial ManagerCyclo Olefin Polymers - COP Europe, Zeon Europe GmbH
  • Shota Arakawa, Researcher, Mitsubishi Gas Chemical Company
  • Stephen Barat, Head of Pre-Clinical and Early Clinical Development, SCYNEXIS
  • Steve Chamberlain, Device Engineering Manager, GSK
  • Suraj Ramachandran, Director, Merck
  • Vikas Jaitely, Senior Manager Pharmaceutical Sciences & CMC Regulatory Intelligence, Merck

Key Highlights this January

  • Engage and interact with like-minded individuals through 5+ hours of dedicated networking time, within the conference programme
  • Gain insight from fellow field experts through our interactive programme structure and our fantastic delegation with representation from all aspects of the industry, as well as cross-industry thought leaders and decision makers
  • Discover new technologies being developed to circumvent common industry hurdles and discuss ways in which to overcome the barriers of implementation
  • Hear case studies about the streamlining of injectable device development – from development to market
  • Interact with regulatory bodies in order to glean insight into the most recent revisions to regulation and the best ways to integrate them into business practices
  • Learn about current drug development programmes which will have an imminent impact on the PFS and Injectable devices sector and discuss the influence which drug development has on device development
  • Discuss patient centricity and the impact of human factors on design processes

For further information and to register, please visit:
http://www.pre-filled-syringes.com/wpn

Early-Bird Rates

  • Register by 28th September and save £400
  • Register by 31st October and save £200
  • Register by 30th November and save £100

About SMi Group

The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

Lilly and Lycia Therapeutics enter into strategic …

Eli Lilly and Company (NYSE: LLY) and Lycia Therapeutics, Inc. today announced a multi-year research collaboration and licensing agreement focused on the discovery, devel...

SK bioscience and GSK start Phase 3 trial of adjuv…

SK bioscience (SK) and GlaxoSmithKline plc (GSK) today announced the initiation of a Phase 3 clinical study of SK's COVID-19 vaccine candidate, GBP510, in combination wit...

Blood vessels produce growth factor that promotes …

Blood vessels supply tumors with nutrients and, on the other hand, enable cancer cells to spread throughout the body. The settlement of circulating tumor cells in a dista...

No serious health effects linked to mRNA COVID-19 …

Federal and Kaiser Permanente researchers combing the health records of 6.2 million patients found no serious health effects that could be linked to the 2 mRNA COVID-19 v...

New study examines 'Achilles heel' of cancer tumou…

Researchers at the University of British Columbia's faculty of medicine and BC Cancer Research Institute have uncovered a weakness in a key enzyme that solid tumour cance...

AI algorithm solves structural biology challenges

Determining the 3D shapes of biological molecules is one of the hardest problems in modern biology and medical discovery. Companies and research institutions often spend ...

First-in-human clinical trial for a vaccine to tre…

The first patients have been enrolled in a phase 1 randomized placebo-controlled clinical trial to study a therapeutic vaccine for opioid use disorder developed by resear...

A drug costing less than €2 a day helps in the tre…

Metoprolol, a drug widely used to treat cardiovascular disease, is beneficial when administered to COVID-19patients. This is the finding of a study by investigators at th...

Rheumatoid arthritis treated with implanted cells …

With a goal of developing rheumatoid arthritis therapies with minimal side effects, researchers at Washington University School of Medicine in St. Louis have genetically ...

Sandoz strengthens pipeline by entering into agree…

Sandoz, a Novartis division, today announced that it has entered into a commercialization agreement with Bio-Thera Solutions, Ltd. for biosimilar bevacizumab (BAT1706). B...

Pfizer and BioNTech submit a variation to EMA with…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that they submitted a variation to the European Medicines Agency (EMA) requesting to update the Condition...

One in three Americans had COVID-19 by the end of …

A new study published in the journal Nature estimates that 103 million Americans, or 31 percent of the U.S. population, had been infected with SARS-CoV-2 by the end of 20...